PCDH17, protocadherin 17, 27253

N. diseases: 51; N. variants: 5
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.410 Biomarker disease PSYGENET Subsequent real-time PCR has shown that mRNA for muscleblind protein 1 (MBNL1) and protocadherin 17 (PCDH17) are increased in BA 46 from subjects with schizophrenia of short, but not long, duration. 17464717 2007
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.410 Biomarker disease BEFREE Subsequent real-time PCR has shown that mRNA for muscleblind protein 1 (MBNL1) and protocadherin 17 (PCDH17) are increased in BA 46 from subjects with schizophrenia of short, but not long, duration. 17464717 2007
CUI: C0036341
Disease: Schizophrenia
Schizophrenia 		0.410 GeneticVariation disease GWASCAT Pleiotropic Meta-Analysis of Cognition, Education, and Schizophrenia Differentiates Roles of Early Neurodevelopmental and Adult Synaptic Pathways. 31374203 2019
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 AlteredExpression disease BEFREE The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer. 31772653 2019
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0005684
Disease: Malignant neoplasm of urinary bladder
Malignant neoplasm of urinary bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0005695
Disease: Bladder Neoplasm
Bladder Neoplasm 		0.050 AlteredExpression disease BEFREE The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer. 31772653 2019
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 and TCF21 methylation levels provided a sensitivity rate of 92% for bladder cancer, 67% for renal cell tumors and 96% for prostate cancer. 21847011 2011
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation is closely associated with bladder cancer malignancy and may be used as an independent predictor of clinical outcomes in patients with bladder cancer. 24567353 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 PosttranslationalModification disease BEFREE PCDH17 promoter methylation was significantly associated with malignant behaviour and poor prognosis of bladder cancer. 24366498 2014
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 Biomarker disease BEFREE The combination of POU4F2/PCDH17 has yielded the highest sensitivity and specificity of 90.00% and 93.96% in all the 312 individuals, showing the capability of detecting BlCa effectively among pathologically varied sample groups. 26700620 2016
CUI: C0699885
Disease: Carcinoma of bladder
Carcinoma of bladder 		0.050 AlteredExpression disease BEFREE The p53 mutation, the expression of p53 and PCDH17 were significantly associated with survival from bladder cancer. 31772653 2019
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 AlteredExpression disease BEFREE PCDH17 protein expression was significantly correlated with low tumour stage and less lymph node metastasis of gastric and colorectal cancer patients, indicating its potential as a tumour marker. 22926751 2013
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 PosttranslationalModification disease BEFREE PCDH17 methylation was significantly associated with higher pathological Gleason score (P=0.0315), advanced pathological stage (P=0.0260), higher level of preoperative PSA (P=0.0354), positive angiolymphatic invasion (P=0.0461), positive lymph node metastasis (P=0.0362), and biochemical recurrence (BCR) (P=0.0018). 25091018 2014
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 PosttranslationalModification disease BEFREE PCDH17 methylation is significantly correlated with advanced stage, higher grade, and lymph node metastasis in ccRCC. 26404644 2015
CUI: C0686619
Disease: Secondary malignant neoplasm of lymph node
Secondary malignant neoplasm of lymph node 		0.040 PosttranslationalModification disease BEFREE Moreover, PCDH17 methylation in serum was significantly correlated with advanced stage (p=0.044), higher grade (p=0.019), lymph node metastasis (p=0.008) and tumor progression (p<0.001). 28688232 2017
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 AlteredExpression disease BEFREE We previously identified PCDH17, encoding protocadherin 17, as a frequently methylated and downregulated tumor suppressor gene (TSG) in gastric and colorectal cancers. 27351130 2016
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 Biomarker disease BEFREE Our previous study showed that the protocadherin 17 (<i>PCDH17</i>) gene was frequently methylated and functioned as a tumor suppressor in CRC. 31815010 2019
CUI: C0009402
Disease: Colorectal Carcinoma
Colorectal Carcinoma 		0.030 AlteredExpression disease BEFREE Thus, PCDH17 acts as a tumour suppressor, exerting its anti-proliferative activity through inducing apoptosis and autophagy, and is frequently silenced in gastric and colorectal cancers. 22926751 2013